Direct compression of adefovir dipivoxil to a 10 mg labelled tablet dose is constrained by low aqueous solubility, cohesive powder behaviour, and the hydrolytic lability of the pivaloyloxymethyl diester moiety. The API is a white to off-white crystalline powder with an officinal description of practically insoluble in water; this places the dissolution rate under immediate-release conditions in dependence on particle size distribution, solid-state form, and superdisintegrant wicking efficiency rather than on simple solubility in the gastric pH range. At a target core weight of 150 mg to 250 mg, the active represents 4.0% to 6.7% w/w of the uncoated tablet mass. The formulation therefore requires a directly compressible diluent with sufficient compactability to absorb the elastic recovery of the API, and a disintegrant concentration that produces rapid tablet rupture without delaying wetting of the poorly wettable prodrug. A lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate blend is mixed in a bin blender at 60% to 70% nominal fill for 300 revolutions; subsequent stratified thief sampling at 10 locations must produce an HPLC assay RSD below 5.0%. Sample locations include top, middle, and bottom zones near the blender discharge; a failure at the discharge port indicates a discharge-induced segregation pattern rather than a true batch heterogeneity. On a high-speed rotary press equipped with 8.0 mm round flat-faced bevel-edge tooling, main compression force is titrated to produce tablets of 5 kP to 10 kP hardness, while pre-compression force is held at 15% to 25% of main compression to promote particle rearrangement without crushing the cohesive API. Tablet friability is evaluated according to USP <1216>; the release criterion is ≤ 1.0% after 100 drum revolutions, but development batches are targeted at ≤ 0.5% to reduce edge chipping in the subsequent aqueous film-coating step. Dissolution testing for an immediate-release adefovir dipivoxil tablet is run under USP <711>; the medium is a validated aqueous buffer selected during development, and the quantitative method is qualified against a reference batch rather than against an unqualified generic condition. The terminal product is an immediate-release film-coated tablet in which a 10 mg prodrug dose is delivered orally; the film is applied as an aqueous HPMC/PEG system in a perforated pan at a bed temperature of 38°C to 42°C and a weight gain of 2.5% to 3.5%. Bed temperature above 45°C is deliberately avoided to prevent surface tack and moisture migration, which generate surface defects and variable coating thickness.

What Limits Aqueous Wet Granulation of a Pivaloyloxymethyl Ester Prodrug?

Aqueous wet granulation of adefovir dipivoxil is not the default route because the diester linkage undergoes hydrolysis in the presence of free water, liberating adefovir, pivalic acid, and formaldehyde. If high-shear granulation is nevertheless required to improve compaction and content uniformity, the granulating fluid should be an ethanol/water mixture at 95:5 v/v; pure aqueous solutions are excluded by design because hydrolysis rates increase sharply when granule moisture exceeds 2.0% w/w. In a top-spray fluid-bed granulator equipped with an inlet air capacity of 100 m³/h per 300 g batch, the binder solution is typically 3.0% to 5.0% w/w povidone K30 in 95:5 ethanol/water, sprayed at 4 mL/min to 8 mL/min with atomizing air pressure of 1.5 bar to 2.5 bar. Inlet air temperature is kept at 40°C to 50°C, and product temperature is maintained below 35°C to limit thermal hydrolysis; final granule loss on drying is specified at ≤ 2.0% by USP <921> method Ia. After drying, granules are milled through a 0.8 mm conidur screen at 1,200 rpm using a low-shear mill; oversize material above 20% w/w indicates over-wetting and is rejected before lubrication. The lubricated mass is compressed to tablets with hardness 6 kP to 9 kP. The terminal dosage form contains adefovir dipivoxil as the labelled prodrug, but the release specification for free adefovir is tightened to ≤ 0.5% w/w because adefovir is more polar and has different permeability characteristics. This limit is enforced through an HPLC method with a C18 column and UV detection at 260 nm. Equipment cleaning after wet granulation is performed with 70% isopropanol followed by dried compressed air meeting ISO 8573-1:2010 class 2.2.1; this sequence avoids residual moisture that would hydrolyse the next batch during the first hour of processing.

Roller-Compacted Granule Process Parameters and Capsule Fill Weight Control

When capsule filling replaces tableting, roller-compacted adefovir dipivoxil granules are preferred because the continuous dry process avoids hydrolytic free-water contact and generates free-flowing granules with controlled bulk density. A representative manufacturing line uses a roll compactor with 200 mm roll diameter and 50 mm roll width, operated at roll force 6 kN/cm to 12 kN/cm, roll speed 3 rpm to 8 rpm, and gap 2.0 mm to 3.0 mm. Ribbons are milled with a 0.8 mm rasp sieve at 500 rpm, and the granule fraction below 125 µm is limited to 30% w/w to prevent capsule weight variation; the fraction above 710 µm is limited to 15% w/w to prevent poor filling on a dosator capsule machine. Size 3 or size 4 hard capsules are filled with a total fill weight of 120 mg to 180 mg; the fill weight RSD must be below 3.0% across 8 hours of continuous operation, with a sampling interval of 30 minutes. The capsule body is selected from HPMC or gelatin; HPMC is specified when ambient relative humidity exceeds 60%, because gelatin shell brittleness at low moisture and softening at high moisture introduce variable disintegration. Disintegration testing under USP <701> uses water at 37°C ± 2°C and is accepted at ≤ 15 minutes; failure above 10 minutes in development triggers reduction of magnesium stearate from 2.0% w/w to 0.75% w/w or switching to sodium stearyl fumarate at 1.0% to 1.5% w/w to reduce hydrophobic film formation. The terminal product includes a 10 mg capsule for oral administration; the capsule is packed in an Alu/Alu blister with 1.0 g silica gel desiccant, because residual free moisture above 3.0% w/w in the granule increases pivalic acid release during 6 months of accelerated stability storage at 40°C/75% RH.

On a sachet or sprinkle granule line, the unit dose is filled by weight rather than compressed, and the dominant stability risk is the hydrolytic degradation of the pivaloyloxymethyl diester rather than mechanical defects. A 10 mg adefovir dipivoxil sachet is compounded as a dry-mix blend of API, mannitol, colloidal silicon dioxide, and a bitter-masking flavouring premix; the blend lubricant is omitted entirely because hydrophobic lubricants delay wetting and produce a gritty mouthfeel when the granules are dispersed in water. The granule is passed through a 1.0 mm screen and filled into a moisture-barrier sachet composed of polyester/aluminium/linear low-density polyethylene with a water vapour transmission rate below 0.05 g/m²/day at 38°C/90% RH. Each sachet contains 2.0 g of a pre-dosed solid mixture, with the API content assayed as 100.0% ± 5.0% of label claim; the precision of the dosing auger on a stick-pack filler is verified at 15-minute intervals, and a fill weight RSD above 2.5% triggers abrasive cleaning of the volumetric cups. The terminal product is a single-dose oral granule that is dispersed in 30 mL of water immediately before administration; the dispersion is not stored for more than 15 minutes because free water initiates ester hydrolysis. The absence of a compression step means no hardness or friability test is applied, but the finished granule is controlled for particle size distribution, loss on drying ≤ 2.0% by USP <921>, and moisture penetration through the laminated film by ASTM F1249-20. A stability study at 25°C/60% RH and 40°C/75% RH is required to establish the storage period; the specification for the free adefovir hydrolysis product is set at ≤ 1.0% w/w for the sachet format, and the formaldehyde-derived adduct level is monitored by a derivatization HPLC method using 2,4-dinitrophenylhydrazine with detection at 350 nm.

If an Injectable Adefovir Dipivoxil Presentation Is Required, Sterile Filtration and pH Control Must Be Re-Evaluated Against Ester Hydrolysis

An injectable adefovir dipivoxil dosage form is not a conventional pharmaceutical product because the prodrug is designed for oral absorption and relies on intestinal and plasma esterases to liberate adefovir. The dipivoxil form has low aqueous solubility at ≤ 0.02 mg/mL and is not readily suitable for a water-for-injection vehicle; a co-solvent system would require a combination of polyethylene glycol 400, propylene glycol, and ethanol in ratios selected by phase-solubility screening, but published data for this specific configuration is limited. If an injectable formulation is advanced as an investigational product, the aqueous phase must be buffered within pH 6.5 to 7.5 because acidic pH accelerates cleavage of the pivaloyloxymethyl esters to pivalic acid and formaldehyde, while alkaline pH promotes base-catalysed hydrolysis of the phosphonate diester. The formulation must be sterile-filtered through a 0.22 µm polyvinylidene fluoride membrane under ISO 14644-1 class 5 conditions; however, a solubility-limited formulation cannot be sterile-filtered if it is presented as a nanosuspension or lipid emulsion, so terminal sterilization by autoclaving at 121°C for 15 minutes is not automatically applicable and must be tested for major degradation product increase. The particle size distribution of an intravenous intermediate must be controlled at D90 ≤ 5 µm, but the neutral diester itself is rapidly hydrolysed by nonspecific esterases in the bloodstream, producing two equivalents of pivalic acid and formaldehyde per molecule; formate and pivalate contribute to anion-gap and mitochondrial CoA sequestration concerns that are dose-limiting. The terminal injectable supply is filled under EU GMP Annex 1 in a restricted-access barrier system with an environmental monitoring plan covering viable and non-viable particles, and the container closure system is selected for break-loose force 1.5 kg to 3.0 kg and reseal integrity under USP <1207>. Because no licensed injectable product establishes a compendial reference, the release specification must include an osmolality limit of 280 mOsm/kg to 320 mOsm/kg for an intravenous preparation, a bacterial endotoxin limit calculated under USP <85>, and a total degradation product specification that includes free adefovir, pivalic acid, and formaldehyde adducts; published data for this specific configuration is limited and animal toxicology would be required before clinical administration.

Residual Pivalic Acid and Formaldehyde Generation in Stored Granules Is a Stability-Limiting Factor

The stability of all solid oral forms of adefovir dipivoxil is governed by the hydrolytic release of pivalic acid and formaldehyde from the two pivaloyloxymethyl ester groups. This reaction proceeds by acid- and base-catalysed mechanisms and is accelerated by raised relative humidity and temperature; therefore the product must be stored in a moisture-impermeable package with desiccant. In accelerated stability testing at 40°C/75% RH, uncoated tablet cores packed in PVC/PVDC blisters show a measurable increase in pivalic acid after 14 days, whereas Alu/Alu blisters with 1.0 g molecular sieve reduce the increase below the limit of a validated GC headspace method; exact values vary with the formulation and are established in the stability protocol. The free adefovir concentration is monitored by HPLC with UV detection at 260 nm using a C18 column and a phosphate buffer/acetonitrile mobile phase; the limit of quantitation is set at 0.05% w/w. Formaldehyde is derivatized with 2,4-dinitrophenylhydrazine and detected at 350 nm; the specification is aligned with ICH M7(R2) acceptable-intake methodology for a mutagenic impurity, but the final numerical limit must be derived from the maximum daily dose of 10 mg, resulting in a conservative threshold in the low ppm range. This stability constraint dictates that any downstream granule or tablet process must minimize residual free water; granule loss on drying is set at ≤ 2.0% w/w, and compression rooms are conditioned to ≤ 30% RH. Packaging operations are conducted at 25°C/35% RH because open storage at room humidity above 55% RH for longer than 1 hour causes visible surface tack and weight increase in unsealed cores. The terminal product therefore contains the labelled 10 mg prodrug with an impurity shelf-life specification that limits free adefovir, pivalic acid, and formaldehyde-derived adducts; a desiccant pouch is mandatory, and the package is sealed within 24 hours of final tablet coating to limit environmental moisture uptake.

When the same oral solid dosage suite is used for adefovir dipivoxil and other nucleotide antivirals such as tenofovir disoproxil fumarate, cleaning validation becomes an application-critical control because the 10 mg labelled dose is small enough to create a low acceptable carryover limit on high-volume equipment. Dedicated or campaign-managed suites are preferred; a shared surface is swabbed from defined contact points after a verified wash cycle, and the analytical method must separate adefovir dipivoxil from its hydrolysis products and from prior-product actives. The cleaning protocol is developed under 21 CFR 211.67 and ICH Q7; the most restrictive permitted carryover is calculated from the health-based exposure limit or clinical dose fraction, and the swab recovery factor is validated over at least 70% of the fortified spike. After cleaning, the production line is dried with lint-free wipers and conditioned air at ≤ 30% RH; any residual water retained in a gasket or dead leg becomes a hydrolytic risk for the next batch because the ester prodrug is sensitive to moisture. The terminal product released from a shared suite must meet the full pharmacopoeial identity, assay, content uniformity, and degradation product monograph of the relevant market; no separate cleaning-related test is applied to the finished tablets or capsules, but the batch record must include the cleaning verification sign-off before line clearance.